{
      "Rank": 149,
      "Acronym": [
            "AMASS"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "One transconjunctival injection of allogeneic ASCs into the LG in one eye.",
            "One transconjunctival injection of Cryostor CS10 into the LG in one eye."
      ],
      "ArmGroupInterventionName": [
            "Drug: ASCs",
            "Drug: Cryostor CS10"
      ],
      "ArmGroupLabel": [
            "Adipose tissue-derived mesenchymal stem cells (ASCs)",
            "Placebo (vehicle, Cryostor CS10)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04615455"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "AMASS is a double-blinded randomized clinical trial with the purpose of investigating whether injection of allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland (LG) results in increased ocular comfort compared to placebo."
      ],
      "BriefTitle": [
            "Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sj\u00f6gren's Syndrome"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "January 1, 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Keratoconjunctivitis Sicca, in Sjogren's Syndrome"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000007766",
            "D000001172",
            "D000001168",
            "D000007592",
            "D000009140",
            "D000012216",
            "D000014987",
            "D000012466",
            "D000009059",
            "D000009057",
            "D000003240",
            "D000001327",
            "D000007154",
            "D000003231",
            "D000003229",
            "D000007634",
            "D000003316"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Lacrimal Apparatus Diseases",
            "Arthritis, Rheumatoid",
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Xerostomia",
            "Salivary Gland Diseases",
            "Mouth Diseases",
            "Stomatognathic Diseases",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Conjunctivitis",
            "Conjunctival Diseases",
            "Keratitis",
            "Corneal Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC11",
            "BC05",
            "BC07",
            "BC17",
            "BC20"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Eye Diseases",
            "Musculoskeletal Diseases",
            "Mouth and Tooth Diseases",
            "Skin and Connective Tissue Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Syndrome",
            "Eye Disease",
            "Keratoconjunctivitis Sicca",
            "Keratoconjunctivitis Sicca",
            "Sjogren's Syndrome",
            "Keratoconjunctivitis"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M7423",
            "M17192",
            "M9816",
            "M14816",
            "M9815",
            "M9938",
            "M3628",
            "M3632",
            "M9773",
            "M11249",
            "M14197",
            "M5475",
            "M16876",
            "M14437",
            "M11171",
            "M11169",
            "M5616",
            "M3781",
            "M9352",
            "M5607",
            "M5605",
            "M9812",
            "M5691"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Eye Diseases",
            "Dry Eye Syndromes",
            "Keratoconjunctivitis Sicca",
            "Sjogren's Syndrome",
            "Keratoconjunctivitis",
            "Lacrimal Apparatus Diseases",
            "Arthritis",
            "Arthritis, Rheumatoid",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases",
            "Xerostomia",
            "Salivary Gland Diseases",
            "Mouth Diseases",
            "Stomatognathic Diseases",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Conjunctivitis",
            "Conjunctival Diseases",
            "Keratitis",
            "Corneal Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000012859",
            "D000015352",
            "D000005128",
            "D000007638",
            "D000007637",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "Sjogren's Syndrome",
            "Dry Eye Syndromes",
            "Eye Diseases",
            "Keratoconjunctivitis Sicca",
            "Keratoconjunctivitis",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "AMASS is a double-blinded randomized clinical trial which will be performed at the Department of Ophthalmology, University Hospital of Copenhagen, Denmark. 40 patients with severe aqueous deficient dry eye disease (ADDE) due to Sj\u00f6gren's Syndrome (SS) will be recruited from the Dept. of Ophthalmology, Rigshospitalet, and allocated in ratio 1:1 to either injection of allogeneic adipose-derived mesenchymal stem cells (ASCs) or placebo (vehicle, Crystore CS10) into the lacrimal gland (LG) in one eye. We hypothesize that injection of allogeneic ASCs into the LG increases tear production and reduce inflammation resulting in increased ocular comfort compared to placebo."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nDiagnosis of Sj\u00f6gren's syndrome according to the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome\nOSDI-score \u2265 33\nSchirmer's test 1-5 mm/5 minutes\nNIKBUT < 10 sec\n\nExclusion Criteria:\n\nLG volume on MRI < 0,2 cm3 in the study eye\nPrevious treatment with ASCs or other stem cell products in the LG(s)\nReduced immune response (e.g. HIV positive)\nPregnancy or planned pregnancy within the next 2 years\nBreastfeeding\nTopical treatment with eye drops other than to treat dry eye disease (DED)\nAny other disease/condition judged by the investigator to be grounds for exclusion, such as infection in or around the eye"
      ],
      "EnrollmentCount": [
            "40"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Adipose tissue-derived mesenchymal stem cells (ASCs)",
            "Placebo (vehicle, Cryostor CS10)"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.",
            "CryoStor\u00ae CS10 freeze medium"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "ASCs",
            "Cryostor CS10"
      ],
      "InterventionOtherName": [
            "Allogeneic adipose-derived mesenchymal stem cells"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "February 15, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "February 14, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Rigshospitalet, Denmark"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Copenhagen"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Denmark"
      ],
      "LocationFacility": [
            "Rigshospitalet"
      ],
      "LocationState": [
            "DK"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "2200"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomized Clinical Trial Evaluating Allogeneic Adipose-derived MesenchymAl Stem Cells as a Treatment of Dry Eye Disease in Patients With Sj\u00f6gren's Syndrome"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Rigshospitalet, Denmark"
      ],
      "OrgStudyId": [
            "2020-002804-38"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Rigshospitalet, Denmark"
      ],
      "OverallOfficialName": [
            "Steffen Heegaard, MD, DMSc"
      ],
      "OverallOfficialRole": [
            "Study Chair"
      ],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 1, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The OSDI is a valid and reliable instrument for measuring dry eye disease severity"
      ],
      "PrimaryOutcomeMeasure": [
            "Ocular Surface Disease Index (OSDI)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "4 months after treatment"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Rigshospitalet, Denmark"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Michael M\u00f8ller-Hansen"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Principal investigator"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "As measured with the Keratograph 5M (Oculus\u2122)",
            "As measured with the Keratograph 5M (Oculus\u2122)",
            "Change in tear production as evaluated with the Schirmer's I test",
            "Change in tear osmolarity measured with TearLab\u2122",
            "Change in staining of the ocular surface (grade 0-5 with 0 being absent corneal staining and 5 being severe corneal staining)",
            "Development of anti-human leucocyte antigen (HLA) anti-bodies evaluated with Luminex HLA anti-body screening\n\nDevelopment of anti-HLA anti-bodies evaluated with Luminex HLA anti-body screening\n\nDevelopment of donor-specific HLA-antibodies"
      ],
      "SecondaryOutcomeMeasure": [
            "Non-invasive keratography tear break-up time (NIKBUT)",
            "Tear meniscus height (TMH)",
            "Schirmer's I test",
            "Tear osmolarity",
            "Oxford scale",
            "HLA anti-bodies"
      ],
      "SecondaryOutcomeTimeFrame": [
            "4 months after treatment",
            "4 months after treatment",
            "4 months after treatment",
            "4 months after treatment",
            "4 months after treatment",
            "12 months after treatment"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "November 3, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "February 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "November 4, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "November 3, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "November 3, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}